You are here:
LinkedIn-button

Partnering

Intravacc has partnerships with universities, government institutions, biotech and pharma companies world-wide. We aim to (co-)develop promising leads further along the vaccine development chain. We specialize in innovative vaccine concepts and offering tailor-made solutions.

 

Partners in developing vaccine concepts

At our facilities we can handle many different vaccines platforms and produce custom-made GMP grade pilot lots to support your phase I or II clinical trials. Currently we have active partnerships ongoing with biotech, and government organizations.

Partners through grants

Together with our partners we also participate in writing grant applications for vaccine concepts and clinical studies. Currently we have several grant sponsored projects running.

Partnering opportunities

At Intravacc we offer non-exclusive partnering opportunities for several proprietary technologies, including:

  • OMV technology
  • Cell-based technology
  • iBoost technology
  • Conjugation technology

 

 

For more information please email bd@intravacc.nl

LinkedIn-button

Our partners

TherapyX

Therapyx, based in Buffalo, NY, is a privately held development-stage biotechnology company committed to innovating our industry and changing the future of pharmaceuticals by engaging in the discovery and development of microparticulate immune therapeutics to treat infectious disease, immune-mediated inflammatory disorders and cancer. Intravacc, collaborates with Therapyx, to further develop and optimize the world's first prophylactic vaccine against gonorrhea, NGoXIM. NGoXIM is a microsphere vaccine with encapsulated interleukin-12 (IL-12) and outer bacterial membrane vesicles from Neisseria gonorrhoeae, developed with Intravacc's OMV platform. This vaccine therefore consists of a combination of adjuvant and antigen, specifically designed for mucosal immunization. In this collaboration, the parties will focus on enhancing and optimizing the specific adaptive immune response in non-human primates as a prelude to testing in humans. This should ultimately lead to a vaccine that provides lasting protection against infection with the Neisseria gonorrhoeae bacteria.

Celonic

Celonic, a Basel based CDMO that has industry leading biologics development platforms and flexible GMP manufacturing services in the field of protein, antibody and cell & gene therapy. For this specific joint vaccine development, Intravacc combines its safe and immunogenic OMV delivery platform with S-proteins expressed by Celonic Group’s industry-leading CHOvolution® mammalian cell expression sytem, in order to generate a highly effective and balanced B and T cell response against SARS-CoV-2. Swiss based Celonic Group will construct cell lines producing the S-protein in high quantities and develop a GMP production process.

Versatope

Versatope Therapeutics, Inc., is a start-up biotechnology company located in Lowell, Mass. at the University of Massachusetts' M2D2 biotech incubator. Intravacc and Versatope are collaborating in order to develop a universal influenza vaccine based on OMV technology. Under the alliance, Intravacc will provide its services to Versatope in bringing their universal influenza vaccine candidate, VT-105, towards their first clinical trials. Versatope’s approach combines diverse genetic variants of influenza strains on a single nano-sized OMV that may provide better cross-strain protection than influenza vaccines comprised of individual strains.

Liaoning Chengda Biotechnology Co., Ltd

Liaoning Chengda Biotechnology CO., Ltd, (CDBIO) is a leading company in the area of human vaccines and related products and technologies in the People’s Republic of China. CDBIO has an ongoing collaboration with Intravacc to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology. Both parties will collaborate to tailor the Nonamen® concept for the Chinese market. Following the successful completion of this phase, CDBIO will receive a license to further develop and commercialize the vaccine.

Changchun BCHT Biotechnology Co

Changchun BCHT Biotechnology Co., established in 2004 and located in Changchun, is a biopharmaceutical enterprise engaging in research, development, production and marketing of vaccines, biologics and peptide drugs.

Intravacc and BCHT are collaborating on the development of a Haemophilus influenzae Type B (HiB) Conjugate Vaccine within the People’s Republic of China. Through this partnerhsip, BCHT obtained Intravacc’s unique Hib conjugate technology to further develop, produce and sell the vaccine. The vaccine consists of a Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled to tetanus toxoid that has shown to be effective in preventing the disease. The Intravacc Hib vaccine technology has already been used for the vaccination of 100s of millions of children and is WHO-prequalified.

CimCure

CimCure is a new generation company founded in 2015, as a spin-off of the VU University Medical Center. CimCure focuses on design and development of a novel class of active cancer vaccines targeting the tumor blood vessels that are common to most solid tumors. The company has discovered and patented multiple highly specific targets and a novel conjugate vaccine technology that can be employed to induce polyclonal antibody responses to targets specific to the tumor (vasculature). The collaboration with CimCure offers Intravacc access to this technology in developing new vaccines and for providing services involving the in-licensed technique in mutually agreed countries. This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Sinovac

Sinovac is a China based Biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines for infectious disease with significant unmet medical need. Intravacc and Sinovac are collaborating in the eradication of Polio through the technology transfer of sIPV vaccine technology.
Sinovac received market authorization for its sIPV vaccine in July 2021

Serum Institute of India

Serum Institute of India Pvt. Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute.

Through its subsidiary Bilthoven Biologicals, SII and Intravacc are collaborating on the development of an sIPV based Polio vaccine. Beyond Polio vaccines Bilthoven Biologicals and Intravacc are collaborating on several undisclosed targets.

LG Chem

Established in 1947, LG Chem has grown to become Korea’s leading chemical company. Intravacc has successfully transferred its sIPV technology to LG Chem and supported implementation at the LG Chem site.

Currently the clinical studies have been completed and market licensure and WHO-prequalification has been obtained. Commercial manufacturing is ongoing as part of the Polio Eradication Campaign.

Beijing Minhai

Beijing Minhai is a company whose main business is the development, production and sales of biological vaccine products. The company was founded in 2004 and is located in the Beijing Daxing Bioengineering and Pharmaceutical Industry Base of Zhongguancun Science and Technology Park.

Intravacc and Minhai have jointly implemented sIPV technology at the Minhai premises. The sIPV vaccine technology has completed Phase II clinical studies.

TherapyX

Therapyx, based in Buffalo, NY, is a privately held development-stage biotechnology company committed to innovating our industry and changing the future of pharmaceuticals by engaging in the discovery and development of microparticulate immune therapeutics to treat infectious disease, immune-mediated inflammatory disorders and cancer. Intravacc, collaborates with Therapyx, to further develop and optimize the world's first prophylactic vaccine against gonorrhea, NGoXIM. NGoXIM is a microsphere vaccine with encapsulated interleukin-12 (IL-12) and outer bacterial membrane vesicles from Neisseria gonorrhoeae, developed with Intravacc's OMV platform. This vaccine therefore consists of a combination of adjuvant and antigen, specifically designed for mucosal immunization. In this collaboration, the parties will focus on enhancing and optimizing the specific adaptive immune response in non-human primates as a prelude to testing in humans. This should ultimately lead to a vaccine that provides lasting protection against infection with the Neisseria gonorrhoeae bacteria.

Liaoning Chengda Biotechnology Co., Ltd

Liaoning Chengda Biotechnology CO., Ltd, (CDBIO) is a leading company in the area of human vaccines and related products and technologies in the People’s Republic of China. CDBIO has an ongoing collaboration with Intravacc to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology. Both parties will collaborate to tailor the Nonamen® concept for the Chinese market. Following the successful completion of this phase, CDBIO will receive a license to further develop and commercialize the vaccine.

Changchun BCHT Biotechnology Co

Changchun BCHT Biotechnology Co., established in 2004 and located in Changchun, is a biopharmaceutical enterprise engaging in research, development, production and marketing of vaccines, biologics and peptide drugs.

Intravacc and BCHT are collaborating on the development of a Haemophilus influenzae Type B (HiB) Conjugate Vaccine within the People’s Republic of China. Through this partnerhsip, BCHT obtained Intravacc’s unique Hib conjugate technology to further develop, produce and sell the vaccine. The vaccine consists of a Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled to tetanus toxoid that has shown to be effective in preventing the disease. The Intravacc Hib vaccine technology has already been used for the vaccination of 100s of millions of children and is WHO-prequalified.

CimCure

CimCure is a new generation company founded in 2015, as a spin-off of the VU University Medical Center. CimCure focuses on design and development of a novel class of active cancer vaccines targeting the tumor blood vessels that are common to most solid tumors. The company has discovered and patented multiple highly specific targets and a novel conjugate vaccine technology that can be employed to induce polyclonal antibody responses to targets specific to the tumor (vasculature). The collaboration with CimCure offers Intravacc access to this technology in developing new vaccines and for providing services involving the in-licensed technique in mutually agreed countries. This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Sinovac

Sinovac is a China based Biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines for infectious disease with significant unmet medical need. Intravacc and Sinovac are collaborating in the eradication of Polio through the technology transfer of sIPV vaccine technology.
Sinovac received market authorization for its sIPV vaccine in July 2021

Serum Institute of India

Serum Institute of India Pvt. Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute.

Through its subsidiary Bilthoven Biologicals, SII and Intravacc are collaborating on the development of an sIPV based Polio vaccine. Beyond Polio vaccines Bilthoven Biologicals and Intravacc are collaborating on several undisclosed targets.

LG Chem

Established in 1947, LG Chem has grown to become Korea’s leading chemical company. Intravacc has successfully transferred its sIPV technology to LG Chem and supported implementation at the LG Chem site.

Currently the clinical studies have been completed and market licensure and WHO-prequalification has been obtained. Commercial manufacturing is ongoing as part of the Polio Eradication Campaign.

Beijing Minhai

Beijing Minhai is a company whose main business is the development, production and sales of biological vaccine products. The company was founded in 2004 and is located in the Beijing Daxing Bioengineering and Pharmaceutical Industry Base of Zhongguancun Science and Technology Park.

Intravacc and Minhai have jointly implemented sIPV technology at the Minhai premises. The sIPV vaccine technology has completed Phase II clinical studies.

NIH

In September 2020, Intravacc was awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68).

EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (AFM). Intravacc will develop an inactivated EV D68 vaccine, based on Intravacc’s proprietary Vero cell technology, from early product selection through to Phase I clinical testing.

LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.